DeepMed Research

Galderma Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: $22.9B

Website: http://www.galderma.com/

Clinical Trials

A Study to Evaluate the Safety Following Injection of GP0045 Compared to Restylane Lyft Lidocaine

Not Applicable

Completed

Conditions: Safety

Interventions: Device: GP0045
Device: Restylane Lyft Lidocaine

First Posted Date: 2017-04-28

Last Posted Date: 2022-08-25

Lead Sponsor: Galderma R&D

Target Recruit Count: 12

Registration Number: NCT03133325

Locations: 🇸🇪
CTC, Uppsala, Sweden

Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Other: No-treatment control
Device: Restylane Lidocaine

First Posted Date: 2017-04-25

Last Posted Date: 2022-08-26

Lead Sponsor: Galderma R&D

Target Recruit Count: 49

Registration Number: NCT03127384

Locations: 🇩🇪
Munich, Munich, Germany
🇩🇪
Darmstadt, Darmstadt, Germany

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Nemolizumab
Drug: Placebo

First Posted Date: 2017-04-04

Last Posted Date: 2019-10-22

Lead Sponsor: Galderma R&D

Target Recruit Count: 226

Registration Number: NCT03100344

Locations: 🇺🇸
Galderma Investigational site, Richmond, Virginia, United States
🇵🇱
Galderma Investigational Site, Łódź, Poland

Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency

Not Applicable

Completed

Conditions: Midface Volume Deficit

Interventions: Device: Restylane Perlane Lidocaine

First Posted Date: 2017-03-31

Last Posted Date: 2023-11-03

Lead Sponsor: Galderma R&D

Target Recruit Count: 169

Registration Number: NCT03097783

Locations: 🇨🇳
Q-Med AB, Shanghai, China

Oracea Soolantra Association in Participants With Severe Rosacea

Phase 4

Completed

Conditions: Rosacea

Interventions: Drug: Ivermectin 1% cream
Drug: Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
Other: Oral placebo capsules

First Posted Date: 2017-03-09

Last Posted Date: 2021-03-16

Lead Sponsor: Galderma R&D

Target Recruit Count: 273

Registration Number: NCT03075891

Locations: 🇺🇸
Private Practice, Metairie, Louisiana, United States
🇭🇺
Private practice, Szolnok, Hungary
🇭🇺
University, Szeged, Hungary

and more 1 locations

Efficacy and Safety of CD5024 1% in Acne Vulgaris

Phase 2

Completed

Conditions: Acne

Interventions: Drug: CD5024 cream placebo
Drug: CD0271/CD1579 gel placebo
Drug: CD0271/CD1579 gel
Drug: CD5024 1% cream

First Posted Date: 2017-01-27

Last Posted Date: 2020-12-11

Lead Sponsor: Galderma R&D

Target Recruit Count: 70

Registration Number: NCT03034460

Locations: 🇨🇦
Galderma Investigational Site (# 8060), Windsor, Ontario, Canada
🇨🇦
Galderma Investigational site, Montreal, Quebec, Canada
🇩🇪
Galderma investigational site, Munster, Germany

Safety and Efficacy of CD10367 in Psoriasis Vulgaris

Phase 2

Completed

Conditions: Psoriasis Vulgaris

Interventions: Drug: CD10367 1% Solution - Non-desquamated zone
Drug: CD10367 3% Solution - Non-desquamated zone
Drug: CD10367 solution placebo - Non-desquamated zone
Drug: Betneval ointment - Non-desquamated zone
Drug: CD10367 3% Solution - Desquamated zone
Drug: CD10367 solution placebo - Desquamated zone

First Posted Date: 2017-01-19

Last Posted Date: 2017-04-05

Lead Sponsor: Galderma R&D

Target Recruit Count: 24

Registration Number: NCT03025282

Locations: 🇫🇷
Galderma Investigational Site, Nice, France

Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds

Not Applicable

Completed

Conditions: Nasolabial Folds in Chinese Population

Interventions: Device: Restylane Defyne
Device: Restylane

First Posted Date: 2016-12-26

Last Posted Date: 2023-11-03

Lead Sponsor: Galderma R&D

Target Recruit Count: 175

Registration Number: NCT03003130

Locations: 🇨🇳
Q-Med AB, Shanghai, China

Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: NP000888
Drug: Vehicle

First Posted Date: 2016-12-16

Last Posted Date: 2018-06-12

Lead Sponsor: Galderma R&D

Target Recruit Count: 61

Registration Number: NCT02995473

Locations: 🇨🇳
Galderma investigational site 5, Taipei, Taiwan
🇨🇳
Galderma Investigational Site, Lincuo, Taoyuan, Taiwan
🇨🇳
Galderma investigational site, Tainan, Taiwan

and more 5 locations

Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Adapalene 0.3% / BPO 2.5% gel

First Posted Date: 2016-10-13

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 50

Registration Number: NCT02932267

Locations: 🇺🇸
Dermresearch, Austin, Texas, United States
🇸🇬
CIDP, Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy